【摘要】：背景目前慢性HBV感染的免疫發(fā)病機(jī)制尚不太清楚。急性自限性HBV感染時(shí)Th1占優(yōu)，宿主啟動(dòng)了強(qiáng)有效的、多克隆的、多特異性的免疫反應(yīng)，，有利于病毒清除和肝功能的恢復(fù)。反之，Th2占優(yōu)時(shí)感染者不能產(chǎn)生強(qiáng)有力的免疫反應(yīng)，不足以及時(shí)有效地清除受染肝細(xì)胞中的病毒，導(dǎo)致感染的慢性化。IL-12有助于分化調(diào)節(jié)Th1/Th2平衡，促使Th0細(xì)胞向Th1方向分化成熟，阻止Th0向Th2方向的發(fā)展，增強(qiáng)細(xì)胞毒性T細(xì)胞的活性，誘導(dǎo)病毒特異性Th細(xì)胞活動(dòng)的發(fā)生，抑制病毒的復(fù)制及表達(dá)。但I(xiàn)L-12在慢性HBV感染者肝臟組織中的表達(dá)及臨床意義尚未見(jiàn)報(bào)道。 目的探討細(xì)胞因子白細(xì)胞介素-12在肝臟組織中表達(dá)與HBV感染慢性化發(fā)病的相關(guān)性，采用SP免疫組化法檢測(cè)慢性HBV感染相關(guān)性肝病患者肝臟組織中IL-12表達(dá)，研究IL-12在疾病進(jìn)展中的可能作用，評(píng)估檢測(cè)慢性HBV感染者肝臟組織IL-12表達(dá)強(qiáng)度作為常規(guī)免疫標(biāo)記的可能性。 方法應(yīng)用半定量SP免疫組化法檢測(cè)107例慢性乙型肝炎，41例乙肝后肝硬化，37例乙肝后肝癌，76例慢性HBsAg攜帶者肝臟組織中IL-12的表達(dá)情況，另選9個(gè)健康人作對(duì)照組。采用常規(guī)生化方法檢測(cè)肝功能，采用ELISA法檢測(cè)HBV血清學(xué)標(biāo)記物，采用熒光定量PCR試劑盒檢測(cè)HBV-DNA。 結(jié)果 1. IL-12主要在肝細(xì)胞胞漿中表達(dá)。半定量分析結(jié)果顯示，IL-12在CHB、肝硬化、HBV相關(guān)性肝癌組織中的表達(dá)水平存在顯著差異(P0.05)。 2. CHB患者IL-12表達(dá)情況與病理分級(jí)的相關(guān)性比較，差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。 3. IL-12在肝癌及癌旁組織中的表達(dá)情況比較，差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。 4. CHB患者IL-12的表達(dá)情況與HBeAg陽(yáng)性、HBV-DNA等因素比較，差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)，CHB患者IL-12的表達(dá)情況與ALT水平比較差異顯著(P0.05)。 5.肝功能正常的慢性HBV感染者中，HBeAg陽(yáng)性者IL-12陰性表達(dá)率顯著高于HBeAg陰性者，HBV-DNA水平高的患者IL-12陰性表達(dá)率高，HBV-DNA水平低的患者IL-12陽(yáng)性表達(dá)率高(P0.05)；免疫耐受者IL-12陰性表達(dá)率高，低或非復(fù)制期者IL-12陽(yáng)性表達(dá)率高(P0.05)。 結(jié)論 1. IL-12在CHB、肝硬化、HBV相關(guān)性肝癌組織中的表達(dá)存在顯著差異，提示IL-12與HBV感染的免疫發(fā)病機(jī)制有關(guān)，可能參與HBV感染的慢性化、疾病的進(jìn)展與轉(zhuǎn)歸。 2.不同HBeAg狀態(tài)及HBV-DNA病毒載量水平的CHB患者肝臟內(nèi)IL-12的表達(dá)差異有統(tǒng)計(jì)學(xué)意義，提示IL-12可能參與HBeAb的產(chǎn)生及HBV的清除。
[Abstract]:Background at present, the immune pathogenesis of chronic HBV infection is still unclear. In acute self-limited HBV infection, Th1 dominates, and the host initiates a highly effective, polyclonal, multi-heterosexual immune response, which is conducive to virus clearance and liver function recovery. On the other hand, when Th2 is dominant, the infected person can not produce a strong immune response, which is not sufficient to remove the virus in the infected liver cells in time and effectively, leading to the chronic infection. IL-12 helps to differentiate and regulate the balance of Th1/Th2. Th0 cells were induced to differentiate and mature towards Th1, to prevent the development of Th0 towards Th2, to enhance the activity of cytotoxic T cells, to induce the activity of virus-specific Th cells, and to inhibit the replication and expression of viruses. However, the expression and clinical significance of IL-12 in the liver tissues of patients with chronic HBV infection have not been reported. Objective to investigate the relationship between the expression of cytokine interleukin-12 (IL-12) in liver tissue and the pathogenesis of chronic HBV infection, and to detect the expression of IL-12 in liver tissue of patients with chronic HBV infection associated liver disease by SP immunohistochemical method. To study the possible role of IL-12 in the progression of the disease and to evaluate the possibility of detecting the expression of IL-12 in liver tissue of chronic HBV infected patients as a routine immunological marker. Methods the expression of IL-12 in the liver tissues of 107 cases of chronic hepatitis B, 41 cases of posthepatitic cirrhosis, 37 cases of liver cancer after hepatitis B and 76 cases of chronic HBsAg carriers were detected by semi-quantitative SP immunohistochemical method. Routine biochemical method was used to detect liver function, ELISA method was used to detect HBV serological marker, and fluorescent quantitative PCR kit was used to detect HBV-DNA.. Result 1. IL-12 is mainly expressed in the cytoplasm of hepatocytes. The results of semi-quantitative analysis showed that there was significant difference in the expression of IL-12 in CHB, cirrhosis and HBV related liver cancer (P0.05). 2. There was no significant difference between the expression of IL-12 and pathological grade in CHB patients (P0.05). 3. There was no significant difference in the expression of IL-12 in liver cancer and adjacent tissues (P0.05). 4. There was no significant difference between the expression of IL-12 and HBeAg and HBV-DNA in CHB patients (P0.05). The expression of IL-12 in), CHB patients was significantly higher than that in ALT (P0.05). 5. In patients with chronic HBV infection with normal liver function, the negative expression rate of IL-12 in HBeAg positive patients was significantly higher than that in HBeAg negative patients, and IL-12 negative expression rate was higher in patients with high HBV-DNA level. The positive expression rate of IL-12 in patients with low HBV-DNA level was high (P0.05). The negative expression rate of IL-12 was high in immune tolerance group, and the positive rate of IL-12 was high in low or non replicating stage (P0.05). Conclusion 1. There were significant differences in the expression of IL-12 in CHB, cirrhosis and HBV associated liver cancer tissues, suggesting that IL-12 is related to the immune pathogenesis of HBV infection, and may be involved in the chronicity of HBV infection and the progression and outcome of HBV infection. 2. There were significant differences in the expression of IL-12 in the liver of CHB patients with different HBeAg status and HBV-DNA viral load, suggesting that IL-12 might be involved in the production of HBeAb and the clearance of HBV.
【學(xué)位授予單位】：安徽醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2013
【分類(lèi)號(hào)】：R512.62

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 凌瑞,王為忠,張洪偉,石梅,劉存亮,楊吉亮,舒啟銀;生長(zhǎng)激素在門(mén)脈高壓癥大出血斷流術(shù)后的應(yīng)用體會(huì)[J];腸外與腸內(nèi)營(yíng)養(yǎng);2001年02期

2 李為蘇,吳性江,韓建明,黎介壽;生長(zhǎng)激素對(duì)門(mén)靜脈高壓癥病人肝蛋白質(zhì)合成的影響[J];腸外與腸內(nèi)營(yíng)養(yǎng);2004年01期

3 曹海波,喻國(guó)萍,石君;重組人生長(zhǎng)激素治療晚期血吸蟲(chóng)病腹水型低蛋白血癥40例觀察[J];中國(guó)醫(yī)師雜志;2001年08期

4 孟家榕,張閩峰,郭以河,劉會(huì)發(fā),林明珠,戴太監(jiān);IGF-1及其受體在乙型病毒性肝炎組織中表達(dá)的臨床意義[J];東南國(guó)防醫(yī)藥;2004年01期

5 鄭雪玲,趙英恒,李瑜元;胰島素樣生長(zhǎng)因子-Ⅰ與肝硬化[J];國(guó)外醫(yī)學(xué)(內(nèi)科學(xué)分冊(cè));2000年02期

6 李多云;胰島素樣生長(zhǎng)因子-1在肝硬化治療中的應(yīng)用[J];國(guó)外醫(yī)學(xué)(流行病學(xué)傳染病學(xué)分冊(cè));2003年01期

7 周?chē)?guó)雄;重組人生長(zhǎng)激素(r-hGH)治療慢性肝病及肝硬化的研究進(jìn)展[J];國(guó)外醫(yī)學(xué)(消化系疾病分冊(cè));1999年03期

8 錢(qián)學(xué)敏;生長(zhǎng)激素抵抗和肝硬化[J];國(guó)外醫(yī)學(xué)(消化系疾病分冊(cè));2001年02期

9 葉靜;胰島素樣生長(zhǎng)因子家族在肝硬化中的變化[J];國(guó)外醫(yī)學(xué)(消化系疾病分冊(cè));2002年03期

10 王若倫,葉曉光;重組生長(zhǎng)激素與人血清白蛋白治療肝硬化低蛋白血癥的療效比較[J];廣州醫(yī)學(xué)院學(xué)報(bào);2001年03期

相關(guān)博士學(xué)位論文 前1條

1 冉江華;rhGH對(duì)SD大鼠肝臟缺血再灌注損傷的保護(hù)及修復(fù)作用[D];昆明醫(yī)學(xué)院;2006年

相關(guān)碩士學(xué)位論文 前9條

1 吳欣;重組人生長(zhǎng)激素對(duì)肝硬化病人蛋白質(zhì)合成作用的影響[D];軍醫(yī)進(jìn)修學(xué)院;2001年

2 郭韻;IGF-1在類(lèi)風(fēng)濕關(guān)節(jié)炎發(fā)病中作用機(jī)制的探討[D];中國(guó)醫(yī)科大學(xué);2003年

3 代偉;生長(zhǎng)激素受體在人胰腺癌組織中的表達(dá)及其臨床意義[D];第一軍醫(yī)大學(xué);2004年

4 單文;黃芪桂枝五物加味湯治療糖尿病周?chē)窠?jīng)病變的實(shí)驗(yàn)研究[D];黑龍江中醫(yī)藥大學(xué);2005年

5 何綠苑;肝硬化患者血清胰島素樣生長(zhǎng)因子測(cè)定的臨床意義[D];浙江大學(xué);2006年

6 馬俊苓;生長(zhǎng)激素對(duì)大鼠急性肝衰竭的影響其機(jī)制的初步探討[D];天津醫(yī)科大學(xué);2007年

7 柯文波;生長(zhǎng)激素聯(lián)合腸內(nèi)營(yíng)養(yǎng)對(duì)肝硬化門(mén)脈高壓癥術(shù)后蛋白質(zhì)代謝及免疫功能的影響[D];華中科技大學(xué);2006年

8 張軍;結(jié)腸癌患者血清IGF-1水平及癌組織VEGF表達(dá)的臨床意義[D];華中科技大學(xué);2006年

9 劉美佳;胰島素樣生長(zhǎng)因子-Ⅰ在慢性肝病患者血清中的測(cè)定及意義[D];吉林大學(xué);2008年

本文編號(hào)：2348403